Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2026 07:00 ET | Source: Castle Biosciences, Inc.

DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

Castle announced new data that confirm that the i31-SLNB accurately predicts SLN positivity and identifies low-risk patients who may safely forgo SLNB.
March 04, 2026 16:30 ET | Source: Castle Biosciences, Inc.

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB

Castle will share new data evaluating DecisionDx-Melanoma’s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity at SSO 2026.
February 19, 2026 17:46 ET | Source: Castle Biosciences, Inc.

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

Castle announced the publication of a validation study in the Journal of the American Academy of Dermatology for its AdvanceAD-Tx test.
December 19, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Castle Biosciences announces inducement grants of 139,494 RSUs to 83 new employees under Nasdaq Listing Rule 5635(c)(4).
December 17, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

New data show DecisionDx-UM combined with PRAME provides superior prediction of metastasis and survival in uveal melanoma compared to NGS.
December 12, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

Castle announced the publication of a new systematic review and meta-analysis related to its TissueCypher test in the Journal of Clinical Gastroenterology.
December 09, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

Castle Biosciences announced the publication of an independent expert consensus paper endorsing the Company’s DecisionDx-Melanoma test.
November 14, 2025 07:00 ET | Source: Castle Biosciences, Inc.

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

Castle will present new data showing the clinical value of DecisionDx-Melanoma in improving sentinel lymph node biopsy decision making at Dermato-Onco2025.
November 03, 2025 16:07 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Reports Third Quarter 2025 Results

Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the third quarter and nine months ended Sept. 30, 2025.
October 26, 2025 15:05 ET | Source: Castle Biosciences, Inc.

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus

Castle announced new data on its TissueCypher® Barrett’s Esophagus test being presented at ACG 2025.